Orexigen Initiates Phase IIa Antipsychotic-Associated Weight Gain Study
Posted on: Friday, 3 October 2008, 12:00 CDT
Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, has initiated its first Phase IIa clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine.
The Phase IIa clinical trial, OZ-101, is designed to examine the effectiveness of OREX-003 in mitigating drug-associated weight gain or other metabolic consequences commonly experienced by patients taking atypical antipsychotic medications, as well as the potential enhancement of antipsychotic activity.
The OZ-101 clinical trial is a double-blind, placebo-controlled clinical trial evaluating the combination of olanzapine plus zonisamide SR versus olanzapine plus placebo in 75 patients with schizophrenia over 16 weeks at nine centers in the US.
The company has also announced that the US Patent and Trademark Office has issued patent providing broad coverage of the use of zonisamide either alone or in combination with other drugs for the treatment of obesity through 2023.
The USPTO has also issued patent which broadly covers zonisamide in combination with various marketed atypical antipsychotics including olanzapine, clozapine, risperidone, quetiapine, aripiprazole and ziprasidone through 2025. Orexigen has licensed both patents on an exclusive basis from Duke University.
Gary Tollefson, president and CEO of Orexigen, said: "Based on our preclinical data, we believe that OREX-003 has the potential to have an improved metabolic profile and be a more effective long-term option in the management of schizophrenia and a number of related conditions."
Source: Datamonitor
Related Articles
- Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
- Geron Initiates Clinical Trial of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Breast Cancer
- Data From Phase II Clinical Trial of Galiximab in Combination With Rituximab in Patients With Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma
- Pfizer Discontinues Clinical Trials for PF-3512676 Combined With Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer
- CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Soft Tissue Sarcomas
- Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
- Idenix Pharmaceuticals Reports Positive 4-Week Data From A Phase IIb Clinical Trial Evaluating Valopicitabine (NM283) Combined With Pegylated Interferon in Treatment-Naive Hepatitis C Patients
- Aphton Corporation Reports Data From Clinical Trial of Insegia in Combination With Chemotherapy in Pancreatic Cancer
- ARIAD Begins Patient Enrollment in Two Clinical Trials of AP23573 in Combination With Cytotoxic Agents; First Trials of AP23573 Led By European Clinical Investigators
- ChemGenex Launches Multi-Center Phase 2 Clinical Trial of Ceflatonin in Combination With Gleevec in Patients With Chronic Myelogenous Leukemia
 |
 |
User Comments (0)
RSS Feeds